{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:11:13Z","timestamp":1790637073098,"version":"4.1.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"Abstract<\/jats:title>\n Background<\/jats:title>\n Glioblastoma is the most common malignant brain tumor in human adults. Despite several improvements in resective as well as adjuvant therapy over the last decades, its overall prognosis remains poor. As a\u00a0means of improving patient outcome, the possibility of enhancing radiation response by using radiosensitizing agents has been tested in an array of studies.<\/jats:p>\n <\/jats:sec>\n Methods<\/jats:title>\n A\u00a0comprehensive review of clinical trials involving radiation therapy in combination with radiosensitizing agents on patients diagnosed with glioblastoma was performed in the National Center for Biotechnology Information\u2019s PubMed database.<\/jats:p>\n <\/jats:sec>\n Results<\/jats:title>\n A total of 96\u00a0papers addressing this matter were published between 1976 and 2021, of which 63\u00a0matched the subject of this paper. All papers were reviewed, and their findings discussed in the context of their underlining mechanisms of radiosensitization.<\/jats:p>\n <\/jats:sec>\n Conclusion<\/jats:title>\n In the history of glioblastoma treatment, several approaches of optimizing radiation-effectiveness using radiosensitizers have been made. Even though several different strategies and agents have been explored, clear evidence of improved patient outcome is still missing. Tissue-selectiveness and penetration of the blood\u2013brain barrier seem to be major roadblocks; nevertheless, modern strategies try to circumvent these obstacles, using novel sensitizers based on preclinical data or alternative ways of delivery.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00066-022-01942-1","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T10:02:53Z","timestamp":1651572173000},"page":"507-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The use of radiosensitizing agents in the therapy of glioblastoma multiforme\u2014a\u00a0comprehensive review"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-4203","authenticated-orcid":false,"given":"Niklas Benedikt","family":"Pepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"6","key":"1942_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3171\/jns.2000.93.6.1003","volume":"93","author":"W Stummer","year":"2000","unstructured":"Stummer\u00a0W, Novotny\u00a0A, Stepp\u00a0H, Goetz\u00a0C, Bise\u00a0K, Reulen\u00a0HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5\u2011aminolevulinic acid-induced porphyrins: a prospective study in 52\u00a0consecutive patients. J\u00a0Neurosurg 93(6):1003\u20131013. https:\/\/doi.org\/10.3171\/jns.2000.93.6.1003","journal-title":"J Neurosurg"},{"issue":"10","key":"1942_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp\u00a0R, Mason\u00a0WP, van den Bent\u00a0MJ et\u00a0al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N\u00a0Engl J Med 352(10):987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"10172","key":"1942_CR3","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger\u00a0U, Tzaridis\u00a0T, Mack\u00a0F et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a\u00a0randomised, open-label, phase 3 trial. Lancet 393(10172):678\u2013688. https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4","journal-title":"Lancet"},{"issue":"560","key":"1942_CR4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1259\/0007-1285-47-560-474","volume":"47","author":"JC Asquith","year":"1974","unstructured":"Asquith\u00a0JC, Foster\u00a0JL, Wilson\u00a0RL (1974) Metronidazole (\u2018Flagyl\u2019). A radiosensitizer of hypoxic cells. Br J Radiol 47(560):474\u2013481. https:\/\/doi.org\/10.1259\/0007-1285-47-560-474","journal-title":"Br J Radiol"},{"issue":"25","key":"1942_CR5","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1056\/NEJM197606172942503","volume":"294","author":"R Urtasun","year":"1976","unstructured":"Urtasun\u00a0R, Band\u00a0P, Chapman\u00a0JD, Feldstein\u00a0ML, Mielke\u00a0B, Fryer\u00a0C (1976) Radiation and high-dose metronidazole in supratentorial glioblastomas. N\u00a0Engl J Med 294(25):1364\u20131367. https:\/\/doi.org\/10.1056\/NEJM197606172942503","journal-title":"N Engl J Med"},{"issue":"9","key":"1942_CR6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/0360-3016(84)90533-9","volume":"10","author":"DS Fulton","year":"1984","unstructured":"Fulton\u00a0DS, Urtasun\u00a0RC, Shin\u00a0KH et\u00a0al (1984) Misonidazole combined with hyperfractionation in the management of malignant glioma. Int J Radiat Oncol Biol Phys 10(9):1709\u20131712. https:\/\/doi.org\/10.1016\/0360-3016(84)90533-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1942_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/0360-3016(84)90534-0","volume":"10","author":"B Stadler","year":"1984","unstructured":"Stadler\u00a0B, Karcher\u00a0KH, Kogelnik\u00a0HD, Szepesi\u00a0T (1984) Misonidazole and irradiation in the treatment of high-grade astrocytomas: further report of the Vienna study group. Int J Radiat Oncol Biol Phys 10(9):1713\u20131717. https:\/\/doi.org\/10.1016\/0360-3016(84)90534-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.radonc.2011.03.004","volume":"100","author":"J Overgaard","year":"2011","unstructured":"Overgaard\u00a0J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck\u2014a systematic review and meta-analysis. Radiother Oncol 100(1):22\u201332. https:\/\/doi.org\/10.1016\/j.radonc.2011.03.004","journal-title":"Radiother Oncol"},{"issue":"3","key":"1942_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0360-3016(92)90880-q","volume":"22","author":"NC Coleman","year":"1992","unstructured":"Coleman\u00a0NC, Noll\u00a0L, Riese\u00a0N, Buswell\u00a0L, Howes\u00a0AE, Loeffler\u00a0JS et\u00a0al (1992) Final report of the phase I trial of continuous infusion etanidazole (SR 2508): a radiation therapy oncology group study. Int J Radiat Oncol Biol Phys 22(3):577\u2013580. https:\/\/doi.org\/10.1016\/0360-3016(92)90880-q","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1942_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/0360-3016(94)90468-5","volume":"29","author":"NE Riese","year":"1994","unstructured":"Riese\u00a0NE, Loeffler\u00a0JS, Wen\u00a0P, Alexander\u00a0E, Black\u00a0PML, Coleman\u00a0CN (1994) A phase I study of etanidazole and radiotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 29(3):617\u2013620. https:\/\/doi.org\/10.1016\/0360-3016(94)90468-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1942_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/s0360-3016(02)04391-2","volume":"55","author":"KJ Marcus","year":"2003","unstructured":"Marcus\u00a0KJ, Dutton\u00a0SC, Barnes\u00a0P, Coleman\u00a0CN, Pomeroy\u00a0SL, Goumnerova\u00a0L et\u00a0al (2003) A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 55(5):1182\u20131185. https:\/\/doi.org\/10.1016\/s0360-3016(02)04391-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s0360-3016(97)00486-0","volume":"40","author":"EL Chang","year":"1998","unstructured":"Chang\u00a0EL, Loeffler\u00a0JS, Riese\u00a0NE, Wen\u00a0PY, Alexander\u00a0E, Black\u00a0PM et\u00a0al (1998) Survival results from a\u00a0phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 40(1):65\u201370. https:\/\/doi.org\/10.1016\/s0360-3016(97)00486-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-08646-y","volume":"7","author":"A Chakhoyan","year":"2017","unstructured":"Chakhoyan\u00a0A, Guillamo\u00a0JS, Collet\u00a0S, Kauffmann\u00a0F, Delcroix\u00a0N, Lechapt-Zalcman\u00a0E et al (2017) FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas. Sci Rep 7(1):1\u20139. https:\/\/doi.org\/10.1038\/s41598-017-08646-y","journal-title":"Sci Rep"},{"key":"1942_CR14","first-page":"163","volume":"46","author":"CH Chang","year":"1977","unstructured":"Chang\u00a0CH (1977) Hyperbaric oxygen and radiation therapy in the management of glioblastoma. Natl Cancer Inst Monogr 46:163\u2013169","journal-title":"Natl Cancer Inst Monogr"},{"issue":"1","key":"1942_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/a:1015832726054","volume":"58","author":"T Beppu","year":"2002","unstructured":"Beppu\u00a0T, Kamada\u00a0K, Yoshida\u00a0Y, Arai\u00a0H, Ogasawara\u00a0K, Ogawa\u00a0A (2002) Change of oxygen pressure in glioblastoma tissue under various conditions. J\u00a0Neurooncol 58(1):47\u201352. https:\/\/doi.org\/10.1023\/a:1015832726054","journal-title":"J Neurooncol"},{"issue":"11","key":"1942_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/BF01209031","volume":"122","author":"K Kohshi","year":"1996","unstructured":"Kohshi\u00a0K, Kinoshita\u00a0Y, Terashima\u00a0H, Konda\u00a0N, Yokota\u00a0A, Soejima\u00a0T (1996) Radiotherapy after hyperbaric oxygenation for malignant gliomas: a\u00a0pilot study. J\u00a0Cancer Res Clin Oncol 122(11):676\u2013678. https:\/\/doi.org\/10.1007\/BF01209031","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"1942_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1023\/a:1022169107872","volume":"61","author":"T Beppu","year":"2003","unstructured":"Beppu\u00a0T, Kamada\u00a0K, Nakamura\u00a0R, Oikawa\u00a0H, Takeda\u00a0M, Fukuda\u00a0T et al (2003) A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. J\u00a0Neurooncol 61(2):161\u2013170. https:\/\/doi.org\/10.1023\/a:1022169107872","journal-title":"J Neurooncol"},{"issue":"1","key":"1942_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0167-8140(02)00406-1","volume":"67","author":"K Ogawa","year":"2003","unstructured":"Ogawa\u00a0K, Yoshii\u00a0Y, Inoue\u00a0O, Toita\u00a0T, Saito\u00a0A, Kakinohana\u00a0Y et al (2003) Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. Radiother Oncol 67(1):63\u201367. https:\/\/doi.org\/10.1016\/s0167-8140(02)00406-1","journal-title":"Radiother Oncol"},{"issue":"7","key":"1942_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6603342","volume":"95","author":"K Ogawa","year":"2006","unstructured":"Ogawa\u00a0K, Yoshii\u00a0Y, Inoue\u00a0O et al (2006) Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas. Br J Cancer 95(7):862\u2013868. https:\/\/doi.org\/10.1038\/sj.bjc.6603342","journal-title":"Br J Cancer"},{"issue":"3","key":"1942_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/jrr\/rrw105","volume":"58","author":"K Yahara","year":"2017","unstructured":"Yahara\u00a0K, Ohguri\u00a0T, Udono\u00a0H, Yamamoto\u00a0J, Tomura\u00a0K, Onoda\u00a0T et\u00a0al (2017) Radiotherapy using IMRT boosts after hyperbaric oxygen therapy with chemotherapy for glioblastoma. J\u00a0Radiat Res 58(3):351\u2013356. https:\/\/doi.org\/10.1093\/jrr\/rrw105","journal-title":"J Radiat Res"},{"issue":"3","key":"1942_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11060-006-9283-1","volume":"82","author":"K Kohshi","year":"2007","unstructured":"Kohshi\u00a0K, Yamamoto\u00a0H, Nakahara\u00a0A, Katoh\u00a0T, Takagi\u00a0M (2007) Fractionated stereotactic radiotherapy using gamma unit after hyperbaric oxygenation on recurrent high-grade gliomas. J\u00a0Neurooncol 82(3):297\u2013303. https:\/\/doi.org\/10.1007\/s11060-006-9283-1","journal-title":"J Neurooncol"},{"issue":"1","key":"1942_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.4103\/2045-9912.229600","volume":"8","author":"L Huang","year":"2018","unstructured":"Huang\u00a0L, Boling\u00a0W, Zhang\u00a0JH (2018) Hyperbaric oxygen therapy as adjunctive strategy in treatment of glioblastoma multiforme. Med Gas Res 8(1):24\u201328. https:\/\/doi.org\/10.4103\/2045-9912.229600","journal-title":"Med Gas Res"},{"issue":"1","key":"1942_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0167-8140(03)00007-0","volume":"67","author":"JM Simon","year":"2003","unstructured":"Simon\u00a0JM, No\u00ebl\u00a0G, Chiras\u00a0J et al (2003) Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. Radiother Oncol 67(1):45\u201351. https:\/\/doi.org\/10.1016\/s0167-8140(03)00007-0","journal-title":"Radiother Oncol"},{"issue":"2","key":"1942_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0167-8140(95)01534-n","volume":"35","author":"RW van der Maazen","year":"1995","unstructured":"van der Maazen\u00a0RW, Thijssen\u00a0HO, Kaanders\u00a0JH et\u00a0al (1995) Conventional radiotherapy combined with carbogen breathing and nicotinamide for malignant gliomas. Radiother Oncol 35(2):118\u2013122. https:\/\/doi.org\/10.1016\/0167-8140(95)01534-n","journal-title":"Radiother Oncol"},{"issue":"3","key":"1942_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0167-8140(96)01792-6","volume":"40","author":"T Pickles","year":"1996","unstructured":"Pickles\u00a0T, Graham\u00a0P, Syndikus\u00a0I, Rheaume\u00a0DE, Duncan\u00a0GG, Green\u00a0A et\u00a0al (1996) Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. Radiother Oncol 40(3):245\u2013247. https:\/\/doi.org\/10.1016\/0167-8140(96)01792-6","journal-title":"Radiother Oncol"},{"issue":"3","key":"1942_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0360-3016(96)00605-0","volume":"37","author":"L Fatigante","year":"1997","unstructured":"Fatigante\u00a0L, Ducci\u00a0F, Cartei\u00a0F, Colosimo\u00a0S, Marini\u00a0C, Prediletto\u00a0R et\u00a0al (1997) Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. Int J Radiat Oncol Biol Phys 37(3):499\u2013504. https:\/\/doi.org\/10.1016\/s0360-3016(96)00605-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1942_CR27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/s0167-8140(97)00076-5","volume":"43","author":"P Lambin","year":"1997","unstructured":"Lambin\u00a0P, Poortmans\u00a0P, Menten\u00a0J, Hamers\u00a0HP (1997) Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas. Radiother Oncol 43(3):324. https:\/\/doi.org\/10.1016\/s0167-8140(97)00076-5","journal-title":"Radiother Oncol"},{"issue":"10","key":"1942_CR28","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1200\/JCO.1999.17.10.3143","volume":"17","author":"R Miralbell","year":"1999","unstructured":"Miralbell\u00a0R, Mornex\u00a0F, Greiner\u00a0R et\u00a0al (1999) Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European organization for research and treatment of cancer trial 22933. J\u00a0Clin Oncol 17(10):3143\u20133149. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3143","journal-title":"J Clin Oncol"},{"issue":"2","key":"1942_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0167-8140(98)00053-x","volume":"48","author":"MC Hulshof","year":"1998","unstructured":"Hulshof\u00a0MC, Rehmann\u00a0CJ, Booij\u00a0J, van Royen\u00a0EA, Bosch\u00a0DA, Gonz\u00e1lez Gonz\u00e1lez\u00a0D (1998) Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a\u00a099mTc-HMPAO SPECT study. Radiother Oncol 48(2):135\u2013142. https:\/\/doi.org\/10.1016\/s0167-8140(98)00053-x","journal-title":"Radiother Oncol"},{"issue":"1","key":"1942_CR30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ijc.10439","volume":"100","author":"C Delmas","year":"2002","unstructured":"Delmas\u00a0C, Heliez\u00a0C, Cohen-Jonathan\u00a0E et al (2002) Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int J Cancer 100(1):43\u201348. https:\/\/doi.org\/10.1002\/ijc.10439","journal-title":"Int J Cancer"},{"issue":"5","key":"1942_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.ijrobp.2007.02.043","volume":"68","author":"EC Moyal","year":"2007","unstructured":"Moyal\u00a0EC, Laprie\u00a0A, Delannes\u00a0M et\u00a0al (2007) Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 68(5):1396\u20131401. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.02.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"22","key":"1942_CR32","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2006.06.2323","volume":"24","author":"TF Cloughesy","year":"2006","unstructured":"Cloughesy\u00a0TF, Wen\u00a0PY, Robins\u00a0HI et al (2006) Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a\u00a0north American brain tumor consortium study. J\u00a0Clin Oncol 24(22):3651\u20133656. https:\/\/doi.org\/10.1200\/JCO.2006.06.2323","journal-title":"J Clin Oncol"},{"issue":"6","key":"1942_CR33","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1215\/15228517-2008-070","volume":"10","author":"R Lustig","year":"2008","unstructured":"Lustig\u00a0R, Mikkelsen\u00a0T, Lesser\u00a0G et\u00a0al (2008) Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol 10(6):1004\u20131009. https:\/\/doi.org\/10.1215\/15228517-2008-070","journal-title":"Neuro Oncol"},{"issue":"5","key":"1942_CR34","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ijrobp.2010.07.1997","volume":"81","author":"PL Nghiemphu","year":"2011","unstructured":"Nghiemphu\u00a0PL, Wen\u00a0PY, Lamborn\u00a0KR et\u00a0al (2011) A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 81(5):1422\u20131427. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.07.1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1942_CR35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ejca","volume":"49","author":"A Ducassou","year":"2013","unstructured":"Ducassou\u00a0A, Uro-Coste\u00a0E, Verrelle\u00a0P et al (2013) \u03b1v\u03b23 integrin and fibroblast growth factor receptor 1 (FGFR1): prognostic factors in a\u00a0phase I\u2013II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. Eur J Cancer 49(9):2161\u20132169. https:\/\/doi.org\/10.1016\/j.ejca","journal-title":"Eur J Cancer"},{"issue":"1","key":"1942_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-017-2624-4","volume":"136","author":"PL Nghiemphu","year":"2018","unstructured":"Nghiemphu\u00a0PL, Ebiana\u00a0VA, Wen\u00a0P et al (2018) Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J\u00a0Neurooncol 136(1):79\u201386. https:\/\/doi.org\/10.1007\/s11060-017-2624-4","journal-title":"J Neurooncol"},{"issue":"8","key":"1942_CR37","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1200\/JCO.1999.17.8.2593","volume":"17","author":"L Kleinberg","year":"1999","unstructured":"Kleinberg\u00a0L, Grossman\u00a0SA, Piantadosi\u00a0S et\u00a0al (1999) Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a\u00a0novel radioenhancer, in newly diagnosed glioblastoma multiforme. J\u00a0Clin Oncol 17(8):2593\u20132603. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2593","journal-title":"J Clin Oncol"},{"issue":"14","key":"1942_CR38","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1200\/JCO.2002.01.096","volume":"20","author":"L Kleinberg","year":"2002","unstructured":"Kleinberg\u00a0L, Grossman\u00a0SA, Carson\u00a0K et\u00a0al (2002) Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a\u00a0phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J\u00a0Clin Oncol 20(14):3149\u20133155. https:\/\/doi.org\/10.1200\/JCO.2002.01.096","journal-title":"J Clin Oncol"},{"issue":"6","key":"1942_CR39","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","volume":"18","author":"J Del Rowe","year":"2000","unstructured":"Del Rowe\u00a0J, Scott\u00a0C, Werner-Wasik\u00a0M, Bahary\u00a0JP, Curran\u00a0WJ, Urtasun\u00a0RC et al (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J\u00a0Clin Oncol 18(6):1254\u20131259. https:\/\/doi.org\/10.1200\/JCO.2000.18.6.1254","journal-title":"J Clin Oncol"},{"issue":"6","key":"1942_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/09553006914551581","volume":"16","author":"JD Zimbrick","year":"1969","unstructured":"Zimbrick\u00a0JD, Ward\u00a0JF, Myers\u00a0LS Jr. (1969) Studies on the chemical basis of cellular radiosensitization by 5\u2011bromouracil substitution in DNA. II. Pulse- and steadystate radiolysis of bromouracil-substituted and unsubstituted DNA. Int J Radiat Biol Relat Stud Phys Chem Med 16(6):525\u2013534","journal-title":"Int J Radiat Biol Relat Stud Phys Chem Med"},{"issue":"5","key":"1942_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/0360-3016(87)90292-6","volume":"13","author":"TJ Kinsella","year":"1987","unstructured":"Kinsella\u00a0TJ, Dobson\u00a0PP, Mitchell\u00a0JB, Fornace\u00a0AJ Jr. (1987) Enhancement of X ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13(5):733\u2013739. https:\/\/doi.org\/10.1016\/0360-3016(87)90292-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1942_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00000421-198710000-00014","volume":"10","author":"D Jackson","year":"1987","unstructured":"Jackson\u00a0D, Kinsella\u00a0T, Rowland\u00a0J et\u00a0al (1987) Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. Am J Clin Oncol 10(5):437\u2013443. https:\/\/doi.org\/10.1097\/00000421-198710000-00014","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1942_CR43","first-page":"33","volume":"6","author":"M Matsutani","year":"1988","unstructured":"Matsutani\u00a0M, Kohno\u00a0T, Nagashima\u00a0T et\u00a0al (1988) Clinical trial of intravenous infusion of bromodeoxyuridine (BUdR) for radiosensitization of malignant brain tumors. Radiat Med 6(1):33\u201339","journal-title":"Radiat Med"},{"issue":"4","key":"1942_CR44","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3171\/jns.1988.69.4.0500","volume":"69","author":"HS Greenberg","year":"1988","unstructured":"Greenberg\u00a0HS, Chandler\u00a0WF, Diaz\u00a0RF et al (1988) Intra-arterial bromodeoxyuridine radiosensitization and radiation in treatment of malignant astrocytomas. J\u00a0Neurosurg 69(4):500\u2013505","journal-title":"J Neurosurg"},{"issue":"2","key":"1942_CR45","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0360-3016(90)90552-u","volume":"19","author":"TJ Hegarty","year":"1990","unstructured":"Hegarty\u00a0TJ, Thornton\u00a0AF, Diaz\u00a0RF et al (1990) Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas. Int J Radiat Oncol Biol Phys 19(2):421\u2013428. https:\/\/doi.org\/10.1016\/0360-3016(90)90552-u","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1942_CR46","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1212\/wnl.44.9.1715","volume":"44","author":"HS Greenberg","year":"1994","unstructured":"Greenberg\u00a0HS, Chandler\u00a0WF, Ensminger\u00a0WD et al (1994) Radiosensitization with carotid intra-arterial bromodeoxyuridine +\/\u2212 5\u2011fluorouracil biomodulation for malignant gliomas. Neurology 44(9):1715\u20131720. https:\/\/doi.org\/10.1212\/wnl.44.9.1715","journal-title":"Neurology"},{"issue":"2","key":"1942_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0360-3016(93)90229-o","volume":"27","author":"RC Urtasun","year":"1993","unstructured":"Urtasun\u00a0RC, Cosmatos\u00a0D, DelRowe\u00a0J et al (1993) Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a\u00a0comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 27(2):207\u2013214. https:\/\/doi.org\/10.1016\/0360-3016(93)90229-o","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1942_CR48","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1200\/JCO.1992.10.2.264","volume":"10","author":"TE Goffman","year":"1992","unstructured":"Goffman\u00a0TE, Dachowski\u00a0LJ, Bobo\u00a0H et al (1992) Long-term follow-up on national cancer institute phase I\/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J\u00a0Clin Oncol 10(2):264\u2013268. https:\/\/doi.org\/10.1200\/JCO.1992.10.2.264","journal-title":"J Clin Oncol"},{"issue":"1","key":"1942_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0360-3016(99)00122-4","volume":"45","author":"MD Groves","year":"1999","unstructured":"Groves\u00a0MD, Maor\u00a0MH, Meyers\u00a0C et al (1999) A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 45(1):127\u2013135. https:\/\/doi.org\/10.1016\/s0360-3016(99)00122-4","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"1942_CR50","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/oxfordjournals.annonc.a058594","volume":"4","author":"EE Vokes","year":"1993","unstructured":"Vokes\u00a0EE, Dolan\u00a0ME, Krishnasamy\u00a0S et al (1993) 5\u2011Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a\u00a0clinical and pharmacologic analysis. Ann Oncol 4(7):591\u2013595. https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a058594","journal-title":"Ann Oncol"},{"issue":"3","key":"1942_CR51","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0360-3016(91)90690-6","volume":"21","author":"TL Phillips","year":"1991","unstructured":"Phillips\u00a0TL, Levin\u00a0VA, Ahn\u00a0DK et\u00a0al (1991) Evaluation of bromodeoxyuridine in glioblastoma multiforme: a\u00a0northern California cancer center phase II study. Int J Radiat Oncol Biol Phys 21(3):709\u2013714. https:\/\/doi.org\/10.1016\/0360-3016(91)90690-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1942_CR52","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ijrobp.2003.08.024","volume":"58","author":"MD Prados","year":"2004","unstructured":"Prados\u00a0MD, Seiferheld\u00a0W, Sandler\u00a0HM et\u00a0al (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58(4):1147\u20131152. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.08.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1942_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-021-01855-5","author":"R Mapelli","year":"2021","unstructured":"Mapelli\u00a0R, Julita\u00a0C, Bianchi\u00a0SP, Gallina\u00a0N, Lucchini\u00a0R, Midulla\u00a0M, Puci\u00a0F, Saddi\u00a0J, Trivellato\u00a0S, Panizza\u00a0D, De Ponti\u00a0E, Arcangeli\u00a0S (2021) Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-021-01855-5","journal-title":"Strahlenther Onkol"},{"issue":"12","key":"1942_CR54","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1093\/neuonc\/nou103","volume":"16","author":"JM Su","year":"2014","unstructured":"Su\u00a0JM, Thompson\u00a0P, Adesina\u00a0A et al (2014) A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a\u00a0pediatric brain tumor consortium report. Neuro Oncol 16(12):1661\u20131668. https:\/\/doi.org\/10.1093\/neuonc\/nou103","journal-title":"Neuro Oncol"},{"issue":"1","key":"1942_CR55","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1038\/s41598-018-22022-4","volume":"8","author":"P Lesueur","year":"2018","unstructured":"Lesueur\u00a0P, Chevalier\u00a0F, El-Habr\u00a0EA et al (2018) Radiosensitization effect of talazoparib, a\u00a0parp inhibitor, on glioblastoma stem cells exposed to low and high linear energy transfer radiation. Sci Rep 8(1):3664. https:\/\/doi.org\/10.1038\/s41598-018-22022-4","journal-title":"Sci Rep"},{"issue":"1","key":"1942_CR56","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4081\/ejh.2012.e9","volume":"56","author":"A Galia","year":"2012","unstructured":"Galia\u00a0A, Calogero\u00a0AE, Condorelli\u00a0R et al (2012) PARP\u20111 protein expression in glioblastoma multiforme. Eur J Histochem 56(1):e9. https:\/\/doi.org\/10.4081\/ejh.2012.e9","journal-title":"Eur J Histochem"},{"issue":"6","key":"1942_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","volume":"22","author":"PA Baxter","year":"2020","unstructured":"Baxter\u00a0PA, Su\u00a0JM, Onar-Thomas\u00a0A et al (2020) A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a\u00a0pediatric brain tumor consortium study. Neuro Oncol 22(6):875\u2013885. https:\/\/doi.org\/10.1093\/neuonc\/noaa016","journal-title":"Neuro Oncol"},{"issue":"2","key":"1942_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-015-1966-z","volume":"126","author":"HI Robins","year":"2016","unstructured":"Robins\u00a0HI, Zhang\u00a0P, Gilbert\u00a0MR et al (2016) A randomized phase I\/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J\u00a0Neurooncol 126(2):309\u2013316. https:\/\/doi.org\/10.1007\/s11060-015-1966-z","journal-title":"J Neurooncol"},{"issue":"12","key":"1942_CR59","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","volume":"22","author":"C Hanna","year":"2020","unstructured":"Hanna\u00a0C, Kurian\u00a0KM, Williams\u00a0K et\u00a0al (2020) Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol 22(12):1840\u20131850. https:\/\/doi.org\/10.1093\/neuonc\/noaa104","journal-title":"Neuro Oncol"},{"issue":"10","key":"1942_CR60","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","volume":"23","author":"HW Sim","year":"2021","unstructured":"Sim\u00a0HW, McDonald\u00a0KL, Lwin\u00a0Z et\u00a0al (2021) A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro Oncol 23(10):1736\u20131749. https:\/\/doi.org\/10.1093\/neuonc\/noab111","journal-title":"Neuro Oncol"},{"issue":"1","key":"1942_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-019-5413-y","volume":"19","author":"P Lesueur","year":"2019","unstructured":"Lesueur\u00a0P, Lequesne\u00a0J, Grellard\u00a0JM et al (2019) Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer 19(1):198. https:\/\/doi.org\/10.1186\/s12885-019-5413-y","journal-title":"BMC Cancer"},{"issue":"2","key":"1942_CR62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3816\/CGC.2008.n.011","volume":"6","author":"RJ Amato","year":"2008","unstructured":"Amato\u00a0RJ, Jac\u00a0J, Hernandez-McClain\u00a0J (2008) Motexafin gadolinium for the treatment of metastatic renal cell carcinoma: phase II study results. Clin Genitourin Cancer 6(2):73\u201378. https:\/\/doi.org\/10.3816\/CGC.2008.n.011","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"1942_CR63","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/JTO.0b013e31820a443f","volume":"6","author":"MJ Edelman","year":"2011","unstructured":"Edelman\u00a0MJ, Otterson\u00a0G, Leach\u00a0J et al (2011) Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J\u00a0Thorac Oncol 6(4):786\u2013789. https:\/\/doi.org\/10.1097\/JTO.0b013e31820a443f","journal-title":"J Thorac Oncol"},{"issue":"20","key":"1942_CR64","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1158\/1078-0432.CCR-09-0905","volume":"15","author":"AM Evens","year":"2009","unstructured":"Evens\u00a0AM, Spies\u00a0WG, Helenowski\u00a0IB et al (2009) The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed\/refractory non-Hodgkin\u2019s lymphoma: preclinical findings and results of a\u00a0phase I trial. Clin Cancer Res 15(20):6462\u20136471. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0905","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1942_CR65","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1215\/15228517-2008-043","volume":"10","author":"KA Bradley","year":"2008","unstructured":"Bradley\u00a0KA, Pollack\u00a0IF, Reid\u00a0JM et\u00a0al (2008) Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a\u00a0children\u2019s oncology group phase I study. Neuro Oncol 10(5):752\u2013758. https:\/\/doi.org\/10.1215\/15228517-2008-043","journal-title":"Neuro Oncol"},{"issue":"7","key":"1942_CR66","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1200\/JCO.2001.19.7.2074","volume":"19","author":"P Carde","year":"2001","unstructured":"Carde\u00a0P, Timmerman\u00a0R, Mehta\u00a0MP et\u00a0al (2001) Multicenter phase Ib\/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J\u00a0Clin Oncol 19(7):2074\u20132083. https:\/\/doi.org\/10.1200\/JCO.2001.19.7.2074","journal-title":"J Clin Oncol"},{"issue":"3","key":"1942_CR67","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ijrobp.2007.04.017","volume":"69","author":"JM Ford","year":"2007","unstructured":"Ford\u00a0JM, Seiferheld\u00a0W, Alger\u00a0JR et al (2007) Results of the phase I dose-escalating study of motexafin gadolinium with standard radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 69(3):831\u2013838. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.04.017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"1942_CR68","doi-asserted-by":"publisher","first-page":"10691","DOI":"10.1074\/jbc.M511373200","volume":"281","author":"SI Hashemy","year":"2006","unstructured":"Hashemy\u00a0SI, Ungerstedt\u00a0JS, Zahedi Avval\u00a0F, Holmgren\u00a0A (2006) Motexafin gadolinium, a\u00a0tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J\u00a0Biol Chem 281(16):10691\u201310697. https:\/\/doi.org\/10.1074\/jbc.M511373200","journal-title":"J Biol Chem"},{"issue":"1","key":"1942_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-005-9101-1","volume":"77","author":"GN Wu","year":"2006","unstructured":"Wu\u00a0GN, Ford\u00a0JM, Alger\u00a0JR (2006) MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J\u00a0Neurooncol 77(1):95\u2013103. https:\/\/doi.org\/10.1007\/s11060-005-9101-1","journal-title":"J Neurooncol"},{"issue":"5","key":"1942_CR70","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ijrobp.2014.12.050","volume":"91","author":"DG Brachman","year":"2015","unstructured":"Brachman\u00a0DG, Pugh\u00a0SL, Ashby\u00a0LS et al (2015) Phase 1\/2 trials of temozolomide, motexafin gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Int J Radiat Oncol Biol Phys 91(5):961\u2013967. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.12.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1942_CR71","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1021\/ja00476a050","volume":"100","author":"BW Metcalf","year":"1978","unstructured":"Metcalf\u00a0BW, Bey\u00a0P, Danzin\u00a0C, Jung\u00a0MJ, Casara\u00a0P, Vevert\u00a0JP (1978) Catalytic irreversible inhibition of mammalian ornithine decarboxylase by substrate and product analogues. J\u00a0Am Chem Soc 100:2551\u20132553","journal-title":"J Am Chem Soc"},{"key":"1942_CR72","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2307\/3577134","volume":"114","author":"CM Arundel","year":"1988","unstructured":"Arundel\u00a0CM, Nishioka\u00a0K, Tofilon\u00a0PJ (1988) Effects of alpha-difluoromethylornithine-induced polyamine depletion on the radiosensitivity of a\u00a0human colon carcinoma cell line. Radiat Res 114:634\u2013640","journal-title":"Radiat Res"},{"issue":"1","key":"1942_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0360-3016(00)01458-9","volume":"49","author":"MD Prados","year":"2001","unstructured":"Prados\u00a0MD, Wara\u00a0WM, Sneed\u00a0PK et\u00a0al (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49(1):71\u201377. https:\/\/doi.org\/10.1016\/s0360-3016(00)01458-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1942_CR74","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/0959-8049(95)95836-U","volume":"31","author":"I Wildfant","year":"1995","unstructured":"Wildfant\u00a0I, Grundel\u00a0O, Schmoll\u00a0H\u2011J (1995) 582 The role of beta-interferon as a\u00a0radiosensitizer in therapy-refractory metastases from solid tumors\u2014a phase-II-study. Eur J Cancer 31:S124","journal-title":"Eur J Cancer"},{"issue":"4","key":"1942_CR75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/cbr.1995.10.265","volume":"10","author":"RO Dillman","year":"1995","unstructured":"Dillman\u00a0RO, Wiemann\u00a0M, Oldham\u00a0RK et al (1995) Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a\u00a0pilot study of the national biotherapy study group. Cancer Biother 10(4):265\u2013271. https:\/\/doi.org\/10.1089\/cbr.1995.10.265","journal-title":"Cancer Biother"},{"issue":"6","key":"1942_CR76","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jnci\/85.6.499","volume":"85","author":"SM Lippman","year":"1993","unstructured":"Lippman\u00a0SM, Kavanagh\u00a0JJ, Paredes-Espinoza\u00a0M et al (1993) 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. J\u00a0Natl Cancer Inst 85(6):499\u2013500. https:\/\/doi.org\/10.1093\/jnci\/85.6.499","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1942_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/neuonc\/3.1.35","volume":"3","author":"RO Dillman","year":"2001","unstructured":"Dillman\u00a0RO, Shea\u00a0WM, Tai\u00a0DF et al (2001) Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro Oncol 3(1):35\u201341. https:\/\/doi.org\/10.1093\/neuonc\/3.1.35","journal-title":"Neuro Oncol"},{"issue":"3","key":"1942_CR78","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/JTO.0b013e3182049d8b","volume":"6","author":"T Sanli","year":"2011","unstructured":"Sanli\u00a0T, Liu\u00a0C, Rashid\u00a0A et\u00a0al (2011) Lovastatin sensitizes lung cancer cells to ionizing radiation: modulation of molecular pathways of radioresistance and tumor suppression. J\u00a0Thorac Oncol 6(3):439\u2013450. https:\/\/doi.org\/10.1097\/JTO.0b013e3182049d8b","journal-title":"J Thorac Oncol"},{"issue":"3","key":"1942_CR79","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/1078-0432.CCR-05-1903","volume":"12","author":"T N\u00fcbel","year":"2006","unstructured":"N\u00fcbel\u00a0T, Damrot\u00a0J, Roos\u00a0WP, Kaina\u00a0B, Fritz\u00a0G (2006) Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res 12(3):933\u2013939. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1903","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1942_CR80","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00000421-199812000-00010","volume":"21","author":"J Larner","year":"1998","unstructured":"Larner\u00a0J, Jane\u00a0J, Laws\u00a0E, Packer\u00a0R, Myers\u00a0C, Shaffrey\u00a0M (1998) A phase I\u2013II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 21(6):579\u2013583. https:\/\/doi.org\/10.1097\/00000421-199812000-00010","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1942_CR81","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11060-018-2786-8","volume":"138","author":"C Happold","year":"2018","unstructured":"Happold\u00a0C, Gorlia\u00a0T, Nabors\u00a0LB et\u00a0al (2018) Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? J\u00a0Neurooncol 138(1):163\u2013171. https:\/\/doi.org\/10.1007\/s11060-018-2786-8","journal-title":"J Neurooncol"},{"issue":"5","key":"1942_CR82","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/0360-3016(94)90492-8","volume":"28","author":"D Haritz","year":"1994","unstructured":"Haritz\u00a0D, Gabel\u00a0D, Huiskamp\u00a0R (1994) Clinical phase\u2011I study of Na2B12H11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT). Int J Radiat Oncol Biol Phys 28(5):1175\u20131181. https:\/\/doi.org\/10.1016\/0360-3016(94)90492-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1942_CR83","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/s0360-3016(02)02862-6","volume":"53","author":"MR Palmer","year":"2002","unstructured":"Palmer\u00a0MR, Goorley\u00a0JT, Kiger\u00a0WS et al (2002) Treatment planning and dosimetry for the Harvard-MIT phase I clinical trial of cranial neutron capture therapy. Int J Radiat Oncol Biol Phys 53(5):1361\u20131379. https:\/\/doi.org\/10.1016\/s0360-3016(02)02862-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR84","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1023\/a:1005741919442","volume":"33","author":"JA Coderre","year":"1997","unstructured":"Coderre\u00a0JA, Elowitz\u00a0EH, Chadha\u00a0M et al (1997) Boron neutron capture therapy for glioblastoma multiforme using p\u2011boronophenylalanine and epithermal neutrons: trial design and early clinical results. J\u00a0Neurooncol 33(1):141\u2013152. https:\/\/doi.org\/10.1023\/a:1005741919442","journal-title":"J Neurooncol"},{"issue":"2","key":"1942_CR85","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/a:1005766828165","volume":"35","author":"M Takagaki","year":"1997","unstructured":"Takagaki\u00a0M, Oda\u00a0Y, Miyatake\u00a0S et\u00a0al (1997) Boron neutron capture therapy: preliminary study of BNCT with sodium borocaptate (Na2B1 2H1 1SH) on glioblastoma. J\u00a0Neurooncol 35(2):177\u2013185. https:\/\/doi.org\/10.1023\/a:1005766828165","journal-title":"J Neurooncol"},{"issue":"4","key":"1942_CR86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/s0360-3016(97)00891-2","volume":"40","author":"M Chadha","year":"1998","unstructured":"Chadha\u00a0M, Capala\u00a0J, Coderre\u00a0JA et al (1998) Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven national laboratory. Int J Radiat Oncol Biol Phys 40(4):829\u2013834. https:\/\/doi.org\/10.1016\/s0360-3016(97)00891-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR87","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF02699940","volume":"62","author":"J Capala","year":"2003","unstructured":"Capala\u00a0J, Stenstam\u00a0BH, Sk\u00f6ld\u00a0K et\u00a0al (2003) Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J\u00a0Neurooncol 62(1):135\u2013144. https:\/\/doi.org\/10.1007\/BF02699940","journal-title":"J Neurooncol"},{"issue":"5","key":"1942_CR88","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.apradiso.2004.05.058","volume":"61","author":"T Kageji","year":"2004","unstructured":"Kageji\u00a0T, Nagahiro\u00a0S, Mizobuchi\u00a0Y, Toi\u00a0H, Nakagawa\u00a0Y, Kumada\u00a0H (2004) Radiation injury of boron neutron capture therapy using mixed epithermal- and thermal neutron beams in patients with malignant glioma. Appl Radiat Isot 61(5):1063\u20131067. https:\/\/doi.org\/10.1016\/j.apradiso.2004.05.058","journal-title":"Appl Radiat Isot"},{"issue":"5","key":"1942_CR89","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.apradiso.2004.05.008","volume":"61","author":"WS Kiger 3rd","year":"2004","unstructured":"Kiger\u00a0WS 3rd, Lu\u00a0XQ, Harling\u00a0OK et\u00a0al (2004) Preliminary treatment planning and dosimetry for a\u00a0clinical trial of neutron capture therapy using a\u00a0fission converter epithermal neutron beam. Appl Radiat Isot 61(5):1075\u20131081. https:\/\/doi.org\/10.1016\/j.apradiso.2004.05.008","journal-title":"Appl Radiat Isot"},{"issue":"5","key":"1942_CR90","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.apradiso.2004.05.010","volume":"61","author":"T Yamamoto","year":"2004","unstructured":"Yamamoto\u00a0T, Matsumura\u00a0A, Nakai\u00a0K et\u00a0al (2004) Current clinical results of the Tsukuba BNCT trial. Appl Radiat Isot 61(5):1089\u20131093. https:\/\/doi.org\/10.1016\/j.apradiso.2004.05.010","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"1942_CR91","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3171\/jns.2005.103.6.1000","volume":"103","author":"S Miyatake","year":"2005","unstructured":"Miyatake\u00a0S, Kawabata\u00a0S, Kajimoto\u00a0Y et\u00a0al (2005) Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J\u00a0Neurosurg 103(6):1000\u20131009. https:\/\/doi.org\/10.3171\/jns.2005.103.6.1000","journal-title":"J Neurosurg"},{"issue":"2","key":"1942_CR92","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-008-9699-x","volume":"91","author":"S Miyatake","year":"2009","unstructured":"Miyatake\u00a0S, Kawabata\u00a0S, Yokoyama\u00a0K et\u00a0al (2009) Survival benefit of Boron neutron capture therapy for recurrent malignant gliomas. J\u00a0Neurooncol 91(2):199\u2013206. https:\/\/doi.org\/10.1007\/s11060-008-9699-x","journal-title":"J Neurooncol"},{"issue":"1","key":"1942_CR93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1269\/jrr.08043","volume":"50","author":"S Kawabata","year":"2009","unstructured":"Kawabata\u00a0S, Miyatake\u00a0S, Kuroiwa\u00a0T et\u00a0al (2009) Boron neutron capture therapy for newly diagnosed glioblastoma. J\u00a0Radiat Res 50(1):51\u201360. https:\/\/doi.org\/10.1269\/jrr.08043","journal-title":"J Radiat Res"},{"issue":"12","key":"1942_CR94","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.apradiso.2011.03.014","volume":"69","author":"S Kawabata","year":"2011","unstructured":"Kawabata\u00a0S, Miyatake\u00a0S, Hiramatsu\u00a0R et al (2011) Phase II clinical study of boron neutron capture therapy combined with X\u2011ray radiotherapy\/temozolomide in patients with newly diagnosed glioblastoma multiforme-study design and current status report. Appl Radiat Isot 69(12):1796\u20131799. https:\/\/doi.org\/10.1016\/j.apradiso.2011.03.014","journal-title":"Appl Radiat Isot"},{"issue":"12","key":"1942_CR95","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.apradiso.2011.04.031","volume":"69","author":"H Aiyama","year":"2011","unstructured":"Aiyama\u00a0H, Nakai\u00a0K, Yamamoto\u00a0T et\u00a0al (2011) A clinical trial protocol for second line treatment of malignant brain tumors with BNCT at University of Tsukuba. Appl Radiat Isot 69(12):1819\u20131822. https:\/\/doi.org\/10.1016\/j.apradiso.2011.04.031","journal-title":"Appl Radiat Isot"},{"issue":"1","key":"1942_CR96","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF02699937","volume":"62","author":"AZ Diaz","year":"2003","unstructured":"Diaz\u00a0AZ (2003) Assessment of the results from the phase I\/II boron neutron capture therapy trials at the Brookhaven national laboratory from a\u00a0clinician\u2019s point of view. J\u00a0Neurooncol 62(1):101\u2013109. https:\/\/doi.org\/10.1007\/BF02699937","journal-title":"J Neurooncol"},{"issue":"2","key":"1942_CR97","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijrobp.2010.02.031","volume":"80","author":"L Kankaanranta","year":"2011","unstructured":"Kankaanranta\u00a0L, Sepp\u00e4l\u00e4\u00a0T, Koivunoro\u00a0H et al (2011) L\u2011boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a\u00a0phase I study. Int J Radiat Oncol Biol Phys 80(2):369\u2013376. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.02.031","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1942_CR98","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1600-0404.2007.00837.x","volume":"116","author":"B H-Stenstam","year":"2007","unstructured":"H\u2011Stenstam B, Pellettieri\u00a0L, Sk\u00f6ld\u00a0K, Rezaei\u00a0A, Brun\u00a0A (2007) Neuropathological postmortem evaluation of BNCT for GBM. Acta Neurol Scand 116(3):169\u2013176. https:\/\/doi.org\/10.1111\/j.1600-0404.2007.00837.x","journal-title":"Acta Neurol Scand"},{"key":"1942_CR99","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.apradiso.2013.12.014","volume":"88","author":"T Kageji","year":"2014","unstructured":"Kageji\u00a0T, Mizobuchi\u00a0Y, Nagahiro\u00a0S, Nakagawa\u00a0Y, Kumada\u00a0H (2014) Correlation between radiation dose and histopathological findings in patients with gliblastoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot 88:20\u201322. https:\/\/doi.org\/10.1016\/j.apradiso.2013.12.014","journal-title":"Appl Radiat Isot"},{"issue":"2","key":"1942_CR100","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.radonc.2006.04.015","volume":"88","author":"R Henriksson","year":"2008","unstructured":"Henriksson\u00a0R, Capala\u00a0J, Michanek\u00a0A et al (2008) Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a\u00a0phase II study evaluating a\u00a0prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol 88(2):183\u2013191. https:\/\/doi.org\/10.1016\/j.radonc.2006.04.015","journal-title":"Radiother Oncol"},{"issue":"1","key":"1942_CR101","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-0404.2009.01267.x","volume":"122","author":"K Sk\u00f6ld","year":"2010","unstructured":"Sk\u00f6ld\u00a0K, H\u2011Stenstam B, Diaz\u00a0AZ, Giusti\u00a0V, Pellettieri\u00a0L, Hopewell JW (2010) Boron neutron capture therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA\u2011f. Acta Neurol Scand 122(1):58\u201362. https:\/\/doi.org\/10.1111\/j.1600-0404.2009.01267.x","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"1942_CR102","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.apradiso.2011.03.022","volume":"69","author":"JW Hopewell","year":"2011","unstructured":"Hopewell\u00a0JW, Gorlia\u00a0T, Pellettieri\u00a0L, Giusti\u00a0V, H\u2011Stenstam B, Sk\u00f6ld\u00a0K (2011) Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl Radiat Isot 69(12):1737\u20131740. https:\/\/doi.org\/10.1016\/j.apradiso.2011.03.022","journal-title":"Appl Radiat Isot"},{"key":"1942_CR103","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.apradiso.2013.11.092","volume":"88","author":"A Sander","year":"2014","unstructured":"Sander\u00a0A, Wosniok\u00a0W, Gabel\u00a0D (2014) Case numbers for a\u00a0randomized clinical trial of boron neutron capture therapy for glioblastoma multiforme. Appl Radiat Isot 88:16\u201319. https:\/\/doi.org\/10.1016\/j.apradiso.2013.11.092","journal-title":"Appl Radiat Isot"},{"key":"1942_CR104","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-021-01844-8","author":"FS Lautenschlaeger","year":"2021","unstructured":"Lautenschlaeger\u00a0FS, Dumke\u00a0R, Schymalla\u00a0M et\u00a0al (2021) Comparison of carbon ion and photon reirradiation for recurrent glioblastoma. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-021-01844-8","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"1942_CR105","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","volume":"7","author":"W Stummer","year":"2006","unstructured":"Stummer\u00a0W, Pichlmeier\u00a0U, Meinel\u00a0T, Wiestler\u00a0OD, Zanella\u00a0F, Reulen\u00a0HJ (2006) Fluorescence-guided surgery with 5\u2011aminolevulinic acid for resection of malignant glioma: a\u00a0randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392\u2013401. https:\/\/doi.org\/10.1016\/S1470-2045(06)70665-9","journal-title":"Lancet Oncol"},{"issue":"5","key":"1942_CR106","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/lsm.20507","volume":"39","author":"TJ Beck","year":"2007","unstructured":"Beck\u00a0TJ, Kreth\u00a0FW, Beyer\u00a0W et al (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5\u2011aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39(5):386\u2013393. https:\/\/doi.org\/10.1002\/lsm.20507","journal-title":"Lasers Surg Med"},{"issue":"3","key":"1942_CR107","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11060-019-03103-4","volume":"141","author":"K Mahmoudi","year":"2019","unstructured":"Mahmoudi\u00a0K, Garvey\u00a0KL, Bouras\u00a0A et al (2019) 5\u2011aminolevulinic acid photodynamic therapy for the treatment of high-grade gliomas. J\u00a0Neurooncol 141(3):595\u2013607. https:\/\/doi.org\/10.1007\/s11060-019-03103-4","journal-title":"J Neurooncol"},{"issue":"5","key":"1942_CR108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/lsm.22933","volume":"50","author":"H Stepp","year":"2018","unstructured":"Stepp\u00a0H, Stummer\u00a0W (2018) 5\u2011ALA in the management of malignant glioma. Lasers Surg Med 50(5):399\u2013419. https:\/\/doi.org\/10.1002\/lsm.22933","journal-title":"Lasers Surg Med"},{"issue":"2","key":"1942_CR109","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3892\/ijmm.2016.2841","volume":"39","author":"K Ueta","year":"2017","unstructured":"Ueta\u00a0K, Yamamoto\u00a0J, Tanaka\u00a0T, Nakano\u00a0Y, Kitagawa\u00a0T, Nishizawa\u00a0S (2017) 5\u2011Aminolevulinic acid enhances mitochondrial stress upon ionizing irradiation exposure and increases delayed production of reactive oxygen species and cell death in glioma cells. Int J Mol Med 39(2):387\u2013398. https:\/\/doi.org\/10.3892\/ijmm.2016.2841","journal-title":"Int J Mol Med"},{"issue":"3","key":"1942_CR110","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3892\/mmr.2014.2991","volume":"11","author":"J Yamamoto","year":"2015","unstructured":"Yamamoto\u00a0J, Ogura\u00a0SI, Shimajiri\u00a0S et al (2015) 5\u2011Aminolevulinic acid-induced protoporphyrin IX with multi-doseionizing irradiation enhances host antitumor response and strongly inhibits tumor growth in experimental glioma in vivo. Mol Med Rep 11(3):1813\u20131819. https:\/\/doi.org\/10.3892\/mmr.2014.2991","journal-title":"Mol Med Rep"},{"key":"1942_CR111","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3892\/or.2014.3618","volume":"33","author":"T Kitagawa","year":"2015","unstructured":"Kitagawa\u00a0T, Yamamoto\u00a0J, Tanaka\u00a0T, Nakano\u00a0Y, Akiba\u00a0D, Ueta\u00a0K, Nishizawa\u00a0S (2015) 5\u2011Aminolevulinic acid strongly enhances delayed intracellular production of reactive oxygen species (ROS) generated by ionizing irradiation: quantitative analyses and visualization of intracellular ROS production in glioma cells in vitro. Oncol Rep 33:583\u2013585. https:\/\/doi.org\/10.3892\/or.2014.3618","journal-title":"Oncol Rep"},{"issue":"3","key":"1942_CR112","doi-asserted-by":"publisher","first-page":"E522","DOI":"10.1016\/j.ijrobp.2015.07.1882","volume":"93","author":"B Wang","year":"2015","unstructured":"Wang\u00a0B, Cvetkovic\u00a0D, Gupta\u00a0R, Chen\u00a0L, Ma\u00a0CMC, Zhang\u00a0Q, Zeng\u00a0J (2015) Radiation therapy combined with 5\u2011aminolevulinic acid: a\u00a0preliminary study with an in vivo mouse model implanted with human PC\u20113 tumor cells. Int J Radiat Oncol Biol Phys 93(3):E522","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"1942_CR113","doi-asserted-by":"publisher","first-page":"165008","DOI":"10.1088\/1361-6560\/ab9776","volume":"65","author":"JV Panetta","year":"2020","unstructured":"Panetta\u00a0JV, Cvetkovic\u00a0D, Chen\u00a0X, Chen\u00a0L, Ma\u00a0CC (2020) Radiodynamic therapy using 15-MV radiation combined with 5\u2011aminolevulinic acid and carbamide peroxide for prostate cancer in vivo. Phys Med Biol 65(16):165008. https:\/\/doi.org\/10.1088\/1361-6560\/ab9776","journal-title":"Phys Med Biol"},{"key":"1942_CR114","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CMAR.S52147","volume":"5","author":"M Gaber","year":"2013","unstructured":"Gaber\u00a0M, Selim\u00a0H, El-Nahas\u00a0T (2013) Prospective study evaluating the radiosensitizing effect of reduced doses of temozolomide in the treatment of Egyptian patients with glioblastoma multiforme. Cancer Manag Res 5:349\u2013356. https:\/\/doi.org\/10.2147\/CMAR.S52147","journal-title":"Cancer Manag Res"},{"issue":"10","key":"1942_CR115","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi\u00a0ME, Diserens\u00a0AC, Gorlia\u00a0T et\u00a0al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N\u00a0Engl J Med 352(10):997\u20131003. https:\/\/doi.org\/10.1056\/NEJMoa043331","journal-title":"N Engl J Med"},{"key":"1942_CR116","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00066-019-01512-y","volume":"196","author":"N Kim","year":"2020","unstructured":"Kim\u00a0N, Chang\u00a0JS, Wee\u00a0CW, Kim\u00a0IA, Chang\u00a0JH, Lee\u00a0HS et al (2020) Validation and optimization of a\u00a0web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma. Strahlenther Onkol 196:58\u201369. https:\/\/doi.org\/10.1007\/s00066-019-01512-y","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"1942_CR117","doi-asserted-by":"publisher","first-page":"e0238238","DOI":"10.1371\/journal.pone.0238238","volume":"15","author":"RO Minea","year":"2020","unstructured":"Minea\u00a0RO, Duc\u00a0TC, Swenson\u00a0SD et al (2020) Developing a\u00a0clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS ONE 15(9):e238238. https:\/\/doi.org\/10.1371\/journal.pone.0238238","journal-title":"PLoS ONE"},{"key":"1942_CR118","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller\u00a0M, Le Rhun\u00a0E (2020) How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat Rev 87:102029. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1942_CR119","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0891-5849(92)90058-o","volume":"12","author":"AC Miller","year":"1992","unstructured":"Miller\u00a0AC, Blakely\u00a0WF (1992) Inhibition of glutathione reductase activity by a\u00a0carbamoylating nitrosourea: effect on cellular radiosensitivity. Free Radic Biol Med 12(1):53\u201362. https:\/\/doi.org\/10.1016\/0891-5849(92)90058-o","journal-title":"Free Radic Biol Med"},{"key":"1942_CR120","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2307\/3572025","volume":"29","author":"WK Sinclair","year":"1966","unstructured":"Sinclair\u00a0WK, Morton\u00a0RA (1966) X\u2011ray sensitivity during the cell generation cycle of cultured Chinese Hamster cells. Radiat Res 29:450\u2013447","journal-title":"Radiat Res"},{"issue":"3","key":"1942_CR121","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1023\/a:1015797713149","volume":"57","author":"C Murphy","year":"2002","unstructured":"Murphy\u00a0C, Pickles\u00a0T, Knowling\u00a0M, Thiesse\u00a0B (2002) Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J\u00a0Neurooncol 57(3):215\u2013220. https:\/\/doi.org\/10.1023\/a:1015797713149","journal-title":"J Neurooncol"},{"issue":"4","key":"1942_CR122","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1212\/01.wnl.0000197792.73656.c2","volume":"66","author":"F Schmidt","year":"2006","unstructured":"Schmidt\u00a0F, Fischer\u00a0J, Herrlinger\u00a0U, Dietz\u00a0K, Dichgans\u00a0J, Weller\u00a0M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66(4):587\u2013589. https:\/\/doi.org\/10.1212\/01.wnl.0000197792.73656.c2","journal-title":"Neurology"},{"issue":"3","key":"1942_CR123","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller\u00a0M, van den Bent\u00a0M, Preusser\u00a0M et\u00a0al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"1942_CR124","first-page":"3101","volume":"36","author":"WN Dahl","year":"1976","unstructured":"Dahl\u00a0WN, Oftebro\u00a0R, Pettersen\u00a0EO, Brustad\u00a0T (1976) Inhibitory and cytotoxic effects of oncovin (vincristine sulfate) on cells of human line NHIK 3025. Cancer Res 36(9):3101\u20133105","journal-title":"Cancer Res"},{"issue":"6","key":"1942_CR125","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/bjc.1979.129","volume":"39","author":"PB Roberts","year":"1979","unstructured":"Roberts\u00a0PB (1979) Radiosensitization of E. coli B\/r by the cytotoxic agent procarbazine: a\u00a0hypoxic cell sensitizer preferentially toxic to aerobic cells and easily oxidized. Br J Cancer 39(6):755\u2013760. https:\/\/doi.org\/10.1038\/bjc.1979.129","journal-title":"Br J Cancer"},{"issue":"14","key":"1942_CR126","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner\u00a0JC, Shaw\u00a0EG, Pugh\u00a0SL et al (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N\u00a0Engl J Med 374(14):1344\u20131355. https:\/\/doi.org\/10.1056\/NEJMoa1500925","journal-title":"N Engl J Med"},{"issue":"3","key":"1942_CR127","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross\u00a0G, Wang\u00a0M, Shaw\u00a0E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J\u00a0Clin Oncol 31(3):337\u2013343. https:\/\/doi.org\/10.1200\/JCO.2012.43.2674","journal-title":"J Clin Oncol"},{"issue":"24","key":"1942_CR128","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.3346\/jkms.2018.33.e167","volume":"33","author":"SH Kim","year":"2018","unstructured":"Kim\u00a0SH, Yoo\u00a0H, Chang\u00a0JH et\u00a0al (2018) Procarbazine and CCNU chemotherapy for recurrent glioblastoma with MGMT promoter methylation. J\u00a0Korean Med Sci 33(24):e167. https:\/\/doi.org\/10.3346\/jkms.2018.33.e167","journal-title":"J Korean Med Sci"},{"issue":"6","key":"1942_CR129","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/jnci\/86.6.441","volume":"86","author":"J Liebmann","year":"1994","unstructured":"Liebmann\u00a0J, Cook\u00a0JA, Fisher\u00a0J, Teague\u00a0D, Mitchell\u00a0JB (1994) In vitro studies of taxol as a\u00a0radiation sensitizer in human tumor cells. J\u00a0Natl Cancer Inst 86(6):441\u2013446. https:\/\/doi.org\/10.1093\/jnci\/86.6.441","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1942_CR130","first-page":"26","volume":"22","author":"MJ Glantz","year":"1995","unstructured":"Glantz\u00a0MJ, Choy\u00a0H, Kearns\u00a0CM, Akerley\u00a0W, Egorin\u00a0MJ (1995) Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol 22(5):26\u201332","journal-title":"Semin. Oncol."},{"issue":"2","key":"1942_CR131","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.1996.14.2.600","volume":"14","author":"MJ Glantz","year":"1996","unstructured":"Glantz\u00a0MJ, Choy\u00a0H, Kearns\u00a0CM et\u00a0al (1996) Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J\u00a0Clin Oncol 14(2):600\u2013609. https:\/\/doi.org\/10.1200\/JCO.1996.14.2.600","journal-title":"J Clin Oncol"},{"issue":"9","key":"1942_CR132","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.1997.15.9.3121","volume":"15","author":"MR Fetell","year":"1997","unstructured":"Fetell\u00a0MR, Grossman\u00a0SA, Fisher\u00a0JD et\u00a0al (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to brain tumor therapy central nervous system consortium. J\u00a0Clin Oncol 15(9):3121\u20133128. https:\/\/doi.org\/10.1200\/JCO.1997.15.9.3121","journal-title":"J Clin Oncol"},{"issue":"2","key":"1942_CR133","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/a:1006386114104","volume":"45","author":"G Fountzilas","year":"1999","unstructured":"Fountzilas\u00a0G, Karavelis\u00a0A, Capizzello\u00a0A et\u00a0al (1999) Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study. J\u00a0Neurooncol 45(2):159\u2013165. https:\/\/doi.org\/10.1023\/a:1006386114104","journal-title":"J Neurooncol"},{"issue":"2","key":"1942_CR134","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00000421-200004000-00010","volume":"23","author":"G Lederman","year":"2000","unstructured":"Lederman\u00a0G, Wronski\u00a0M, Arbit\u00a0E et\u00a0al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23(2):155\u2013159. https:\/\/doi.org\/10.1097\/00000421-200004000-00010","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1942_CR135","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/153303460700600303","volume":"6","author":"H Ashamalla","year":"2007","unstructured":"Ashamalla\u00a0H, Zaki\u00a0B, Mokhtar\u00a0B et\u00a0al (2007) Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. Technol Cancer Res Treat 6(3):169\u2013176. https:\/\/doi.org\/10.1177\/153303460700600303","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"1942_CR136","first-page":"2829","volume":"6","author":"C Li","year":"2000","unstructured":"Li\u00a0C, Ke\u00a0S, Wu\u00a0QP et al (2000) Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin Cancer Res 6(7):2829\u20132834","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1942_CR137","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/COC.0b013e31827de92b","volume":"37","author":"S Jeyapalan","year":"2014","unstructured":"Jeyapalan\u00a0S, Boxerman\u00a0J, Donahue\u00a0J et al (2014) Paclitaxel poliglumex, temozolomide, and radiation for newly diagnosed high-grade glioma: a\u00a0Brown university oncology group study. Am J Clin Oncol 37(5):444\u2013449. https:\/\/doi.org\/10.1097\/COC.0b013e31827de92b","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1942_CR138","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/COC.0000000000000247","volume":"41","author":"H Elinzano","year":"2018","unstructured":"Elinzano\u00a0H, Glantz\u00a0M, Mrugala\u00a0M et\u00a0al (2018) PPX and concurrent radiation for newly diagnosed glioblastoma without MGMT methylation: a randomized phase II study: brUOG 244. Am J Clin Oncol 41(2):159\u2013162. https:\/\/doi.org\/10.1097\/COC.0000000000000247","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"1942_CR139","first-page":"1085","volume":"16","author":"E Ojima","year":"2006","unstructured":"Ojima\u00a0E, Inoue\u00a0Y, Watanabe\u00a0H et al (2006) The optimal schedule for 5\u2011fluorouracil radiosensitization in colon cancer cell lines. Oncol Rep 16(5):1085\u20131091","journal-title":"Oncol Rep"},{"issue":"10","key":"1942_CR140","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3109\/09553002.2013.797620","volume":"89","author":"G Valdes","year":"2013","unstructured":"Valdes\u00a0G, Iwamoto\u00a0KS (2013) Re-evaluation of cellular radiosensitization by 5\u2011fluorouracil: high-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration. Int J Radiat Biol 89(10):851\u2013862. https:\/\/doi.org\/10.3109\/09553002.2013.797620","journal-title":"Int J Radiat Biol"},{"issue":"5","key":"1942_CR141","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3171\/jns.1992.76.5.0772","volume":"76","author":"WR Shapiro","year":"1992","unstructured":"Shapiro\u00a0WR, Green\u00a0SB, Burger\u00a0PC et al (1992) A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5\u2011fluorouracil, for newly diagnosed patients with malignant glioma. J\u00a0Neurosurg 76(5):772\u2013781. https:\/\/doi.org\/10.3171\/jns.1992.76.5.0772","journal-title":"J Neurosurg"},{"issue":"10","key":"1942_CR142","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1078-0432.CCR-09-3151","volume":"16","author":"JM Grunda","year":"2010","unstructured":"Grunda\u00a0JM, Fiveash\u00a0J, Palmer\u00a0CA et\u00a0al (2010) Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clin Cancer Res 16(10):2890\u20132898. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-3151","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1942_CR143","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000421-199502000-00001","volume":"18","author":"JM Larner","year":"1995","unstructured":"Larner\u00a0JM, Phillips\u00a0CD, Dion\u00a0JE, Jensen\u00a0ME, Newman\u00a0SA, Jane\u00a0JA (1995) A phase 1\u20132 trial of superselective carboplatin, low-dose infusional 5\u2011fluorouracil and concurrent radiation for high-grade gliomas. Am J Clin Oncol 18(1):1\u20137. https:\/\/doi.org\/10.1097\/00000421-199502000-00001","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1942_CR144","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00000421-199502000-00001","volume":"86","author":"P Menei","year":"1999","unstructured":"Menei\u00a0P, Venier\u00a0MC, Gamelin\u00a0E et al (1999) Local and sustained delivery of 5\u2011fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a\u00a0pilot study. Cancer 86(2):325\u2013330. https:\/\/doi.org\/10.1097\/00000421-199502000-00001","journal-title":"Cancer"},{"key":"1942_CR145","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-7091-6090-9_9","volume":"88","author":"P Menei","year":"2003","unstructured":"Menei\u00a0P, Benoit\u00a0JP (2003) Implantable drug-releasing biodegradable microspheres for local treatment of brain glioma. Acta Neurochir Suppl 88:51\u201355. https:\/\/doi.org\/10.1007\/978-3-7091-6090-9_9","journal-title":"Acta Neurochir Suppl"},{"issue":"1","key":"1942_CR146","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/annonc\/mdn543","volume":"20","author":"J Sigmond","year":"2009","unstructured":"Sigmond\u00a0J, Honeywell\u00a0RJ, Postma\u00a0TJ et\u00a0al (2009) Gemcitabine uptake in glioblastoma multiforme: potential as a\u00a0radiosensitizer. Ann Oncol 20(1):182\u2013187. https:\/\/doi.org\/10.1093\/annonc\/mdn543","journal-title":"Ann Oncol"},{"issue":"1","key":"1942_CR147","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.10-1-34","volume":"10","author":"B Pauwels","year":"2005","unstructured":"Pauwels\u00a0B, Korst\u00a0AE, Lardon\u00a0F, Vermorken\u00a0JB (2005) Combined modality therapy of gemcitabine and radiation. Oncologist 10(1):34\u201351. https:\/\/doi.org\/10.1634\/theoncologist.10-1-34","journal-title":"Oncologist"},{"issue":"2","key":"1942_CR148","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00280-009-1155-x","volume":"65","author":"G Metro","year":"2010","unstructured":"Metro\u00a0G, Fabi\u00a0A, Mirri\u00a0MA et\u00a0al (2010) Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. Cancer Chemother Pharmacol 65(2):391\u2013397. https:\/\/doi.org\/10.1007\/s00280-009-1155-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1942_CR149","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-007-9489-x","volume":"87","author":"A Fabi","year":"2008","unstructured":"Fabi\u00a0A, Mirri\u00a0A, Felici\u00a0A et al (2008) Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a\u00a0dose-finding study. J\u00a0Neurooncol 87(1):79\u201384. https:\/\/doi.org\/10.1007\/s11060-007-9489-x","journal-title":"J Neurooncol"},{"issue":"2","key":"1942_CR150","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1023\/a:1019641314661","volume":"59","author":"W Wick","year":"2002","unstructured":"Wick\u00a0W, Hermisson\u00a0M, Kortmann\u00a0RD et\u00a0al (2002) Neoadjuvant gemcitabine\/treosulfan chemotherapy for newly diagnosed glioblastoma: a\u00a0phase II study. J\u00a0Neurooncol 59(2):151\u2013155. https:\/\/doi.org\/10.1023\/a:1019641314661","journal-title":"J Neurooncol"},{"issue":"2","key":"1942_CR151","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/1097-0142(20010115)91:2<423::AID-CNCR1017>3.0.CO;2-H","volume":"91","author":"M Weller","year":"2001","unstructured":"Weller\u00a0M, Streffer\u00a0J, Wick\u00a0W et al (2001) Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study. Cancer 91(2):423\u2013427. https:\/\/doi.org\/10.1002\/1097-0142(20010115)91:2\u3008423::aid-cncr1017\u30093.0.co;2\u2011h","journal-title":"Cancer"},{"issue":"3","key":"1942_CR152","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1023\/a:1008336607135","volume":"11","author":"SZ Gertler","year":"2000","unstructured":"Gertler\u00a0SZ, MacDonald\u00a0D, Goodyear\u00a0M et al (2000) NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol 11(3):315\u2013318. https:\/\/doi.org\/10.1023\/a:1008336607135","journal-title":"Ann Oncol"},{"issue":"20","key":"1942_CR153","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1021\/acs.jmedchem.9b01147","volume":"62","author":"Z Jiang","year":"2019","unstructured":"Jiang\u00a0Z, Pflug\u00a0K, Usama\u00a0SM et al (2019) Cyanine-gemcitabine conjugates as targeted theranostic agents for glioblastoma tumor cells. J\u00a0Med Chem 62(20):9236\u20139245. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01147","journal-title":"J Med Chem"},{"issue":"16","key":"1942_CR154","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.2217\/nnm-2018-0057","volume":"13","author":"C Bastiancich","year":"2018","unstructured":"Bastiancich\u00a0C, Lemaire\u00a0L, Bianco\u00a0J et al (2018) Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models. Nanomedicine (Lond) 13(16):1999\u20132013. https:\/\/doi.org\/10.2217\/nnm-2018-0057","journal-title":"Nanomedicine (Lond)"},{"issue":"5","key":"1942_CR155","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/1541-7786.MCR-04-0032","volume":"3","author":"HJ Boeckman","year":"2005","unstructured":"Boeckman\u00a0HJ, Trego\u00a0KS, Turchi\u00a0JJ (2005) Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res 3(5):277\u2013285. https:\/\/doi.org\/10.1158\/1541-7786.MCR-04-0032","journal-title":"Mol Cancer Res"},{"issue":"24","key":"1942_CR156","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1200\/JCO.2005.04.6979","volume":"24","author":"JC Buckner","year":"2006","unstructured":"Buckner\u00a0JC, Ballman\u00a0KV, Michalak\u00a0JC et al (2006) Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: north central cancer treatment group 93-72-52 and southwest oncology group 9503 trials. J\u00a0Clin Oncol 24(24):3871\u20133879. https:\/\/doi.org\/10.1200\/JCO.2005.04.6979","journal-title":"J Clin Oncol"},{"issue":"1","key":"1942_CR157","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1023\/a:1006201909435","volume":"44","author":"MJ van den Bent","year":"1999","unstructured":"van den Bent\u00a0MJ, Pronk\u00a0L, Sillevis Smitt\u00a0PA, Vecht\u00a0CJ, Eskens\u00a0FA, Verweij\u00a0J (1999) Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. J\u00a0Neurooncol 44(1):59\u201364. https:\/\/doi.org\/10.1023\/a:1006201909435","journal-title":"J Neurooncol"},{"issue":"1","key":"1942_CR158","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1038\/s41598-019-42001-7","volume":"9","author":"J Enr\u00edquez P\u00e9rez","year":"2019","unstructured":"Enr\u00edquez P\u00e9rez\u00a0J, Fritzell\u00a0S, Kopecky\u00a0J, Visse\u00a0E, Darabi\u00a0A, Siesj\u00f6\u00a0P (2019) The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model. Sci Rep 9(1):5632. https:\/\/doi.org\/10.1038\/s41598-019-42001-7","journal-title":"Sci Rep"},{"key":"1942_CR159","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00066-021-01835-9","volume":"197","author":"JLY Chen","year":"2021","unstructured":"Chen\u00a0JLY, Pan\u00a0CK, Lin\u00a0YL et\u00a0al (2021) Preclinical evaluation of PEGylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer. Strahlenther Onkol 197:1131\u20131142. https:\/\/doi.org\/10.1007\/s00066-021-01835-9","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1942_CR160","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11060-013-1238-8","volume":"115","author":"G Charest","year":"2013","unstructured":"Charest\u00a0G, Sanche\u00a0L, Fortin\u00a0D, Mathieu\u00a0D, Paquette\u00a0B (2013) Optimization of the route of platinum drugs administration to optimize the concomitant treatment with radiotherapy for glioblastoma implanted in the Fischer rat brain. J\u00a0Neurooncol 115(3):365\u2013373. https:\/\/doi.org\/10.1007\/s11060-013-1238-8","journal-title":"J Neurooncol"},{"issue":"1","key":"1942_CR161","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijrobp.2011.10.054","volume":"84","author":"G Charest","year":"2012","unstructured":"Charest\u00a0G, Sanche\u00a0L, Fortin\u00a0D, Mathieu\u00a0D, Paquette\u00a0B (2012) Glioblastoma treatment: bypassing the toxicity of platinum compounds by using liposomal formulation and increasing treatment efficiency with concomitant radiotherapy. Int J Radiat Oncol Biol Phys 84(1):244\u2013249. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.10.054","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1942_CR162","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11060-020-03600-x","volume":"149","author":"H Elleaume","year":"2020","unstructured":"Elleaume\u00a0H, Barth\u00a0RF, Rousseau\u00a0J et al (2020) Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma. J\u00a0Neurooncol 149(2):193\u2013208. https:\/\/doi.org\/10.1007\/s11060-020-03600-x","journal-title":"J Neurooncol"},{"issue":"3","key":"1942_CR163","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.18632\/oncotarget.6320","volume":"7","author":"M Niyazi","year":"2016","unstructured":"Niyazi\u00a0M, Harter\u00a0PN, Hattingen\u00a0E et\u00a0al (2016) Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget 7(3):2313\u20132328. https:\/\/doi.org\/10.18632\/oncotarget.6320","journal-title":"Oncotarget"},{"issue":"16","key":"1942_CR164","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMcibr1309402","volume":"369","author":"S Das","year":"2013","unstructured":"Das\u00a0S, Marsden\u00a0PA (2013) Angiogenesis in glioblastoma. N\u00a0Engl J Med 369(16):1561\u20131563. https:\/\/doi.org\/10.1056\/NEJMcibr1309402","journal-title":"N Engl J Med"},{"issue":"5","key":"1942_CR165","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ijrobp.2009.12.010","volume":"76","author":"MC McGee","year":"2010","unstructured":"McGee\u00a0MC, Hamner\u00a0JB, Williams\u00a0RF et\u00a0al (2010) Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 76(5):1537\u20131545. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1942_CR166","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canrad.2017.06.013","volume":"22","author":"A Schernberg","year":"2018","unstructured":"Schernberg\u00a0A, Dhermain\u00a0F, Ammari\u00a0S et al (2018) Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients. Cancer Radiother 22(1):9\u201316. https:\/\/doi.org\/10.1016\/j.canrad.2017.06.013","journal-title":"Cancer Radiother"},{"issue":"30","key":"1942_CR167","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh\u00a0JJ, Desjardins\u00a0A, Herndon\u00a0JE 2nd et\u00a0al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J\u00a0Clin Oncol 25(30):4722\u20134729. https:\/\/doi.org\/10.1200\/JCO.2007.12.2440","journal-title":"J Clin Oncol"},{"issue":"8","key":"1942_CR168","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot\u00a0OL, Wick\u00a0W, Mason\u00a0W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N\u00a0Engl J Med 370(8):709\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"8","key":"1942_CR169","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert\u00a0MR, Dignam\u00a0JJ, Armstrong\u00a0TS et\u00a0al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N\u00a0Engl J Med 370(8):699\u2013708. https:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"20","key":"1942_CR170","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick\u00a0W, Gorlia\u00a0T, Bendszus\u00a0M et\u00a0al (2017) Lomustine and bevacizumab in progressive glioblastoma. N\u00a0Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"key":"1942_CR171","volume-title":"Gliome, S2k-Leitlinie","author":"W Wick","year":"2021","unstructured":"Wick\u00a0W et al (2021) Gliome, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie"},{"issue":"4","key":"1942_CR172","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00259-010-1690-z","volume":"38","author":"FW Floeth","year":"2011","unstructured":"Floeth\u00a0FW, Sabel\u00a0M, Ewelt\u00a0C, Stummer\u00a0W, Felsberg\u00a0J, Reifenberger\u00a0G, Steiger\u00a0HJ, Stoffels\u00a0G, Coenen\u00a0HH, Langen\u00a0KJ (2011) Comparison of (18)F-FET PET and 5\u2011ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging 38(4):731\u2013741. https:\/\/doi.org\/10.1007\/s00259-010-1690-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1942_CR173","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.neuchi.2019.04.005","volume":"65","author":"T Picart","year":"2019","unstructured":"Picart\u00a0T, Berhouma\u00a0M, Dumot\u00a0C, Pallud\u00a0J, Metellus\u00a0P, Armoiry\u00a0X, Guyotat\u00a0J (2019) Optimization of high-grade glioma resection using 5\u2011ALA fluorescence-guided surgery: a literature review and practical recommendations from the neuro-oncology club of the French society of neurosurgery. Neurochirurgie 65(4):164\u2013177. https:\/\/doi.org\/10.1016\/j.neuchi.2019.04.005","journal-title":"Neurochirurgie"},{"issue":"6","key":"1942_CR174","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1751-1097.2010.00799.x","volume":"86","author":"A Johansson","year":"2010","unstructured":"Johansson\u00a0A, Palte\u00a0G, Schnell\u00a0O, Tonn\u00a0JC, Herms\u00a0J, Stepp\u00a0H (2010) 5\u2011Aminolevulinic acid-induced protoporphyrin IX levels in tissue of human malignant brain tumors. Photochem Photobiol 86(6):1373\u20131378. https:\/\/doi.org\/10.1111\/j.1751-1097.2010.00799.x","journal-title":"Photochem Photobiol"},{"issue":"8","key":"1942_CR175","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00066-021-01774-5","volume":"197","author":"X Zhang","year":"2021","unstructured":"Zhang\u00a0X, Bobeica\u00a0M, Unger\u00a0M et\u00a0al (2021) Focused ultrasound radiosensitizes human cancer cells by enhancement of DNA damage. Strahlenther Onkol 197(8):730\u2013743. https:\/\/doi.org\/10.1007\/s00066-021-01774-5","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-01942-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-01942-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:15:17Z","timestamp":1653326117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-01942-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":175,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-01942-1","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.B.\u00a0Pepper, W.\u00a0Stummer and H.T.\u00a0Eich declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}